The “Patent Cliff” Isn’t Just a Pharma Problem—It’s a Talent Problem.
Most people talk about the patent cliff like it’s a spreadsheet event: revenue declines when exclusivity ends, generics arrive, margins compress, and leadership scrambles. But there’…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Branded drug inventory risk isn’t just a balance-sheet problem—it’s a timing problem.
For wholesalers, the pain is familiar: you buy branded product with co…

Big Pharma doesn’t just “hire.” It signals.
And one of the most underappreciated signals is what happens around the patent cliff—when blockbuster protections expire, margins compress, and the future suddenly becomes a hiring plan, not a slide deck.
A n…

Biosimilar switching isn’t a procurement problem—it’s an IP strategy problem.
If you’re planning a biosimilar switch this year, here’s the uncomfortable truth: most teams don’t lose because the biosimilar isn’t available. They lose because the timing i…

Pharma has a familiar playbook: take an old drug, reframe it as “new,” and price it like it’s never been used before.
That’s the core tension behind the latest discussion from DrugPatentWatch: how companies justify premium pricing for repurposed medici…

Pharma recruiters don’t just “find talent.” They find signal.
In a market where everyone claims they’re building the next breakthrough, the real differentiator is often quieter: who has been cited—again and again—by the scientific record.
That’s the co…

Old Drugs. New Prices. Same Molecule. Why Pharma Keeps Winning the Premium Argument.
There’s a familiar script playing out across healthcare systems: a medicine that’s been around for years—sometimes decades—gets repurposed for a new indication, rebran…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in the global drug supply chain. In practice, it’s a signal flare—one that can help investors, manufacturers, and policymakers anticipate where Russia is headed next in APIs and full-cycle drug p…

Europe’s patent system is supposed to be a referee—not a loophole. But a growing body of evidence suggests the game is being played differently: big pharma can use “divisional” patent strategies to delay final decisions, stretching uncertainty long aft…